Epidermal Growth Factor Receptor—Negative Colorectal Cancer: Is There Truly Such an Entity?

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Epidermal growth factor.

1990 • 1,645 citations

The EGF receptor family as targets for cancer therapy

2000 • 1,339 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 • 1,081 citations

Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues

2004 • 320 citations

Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters.

1982 • 271 citations

High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses.

1990 • 150 citations

A structure-based model for ligand binding and dimerization of EGF receptors

2004 • 127 citations

The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function

2004 • 104 citations

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

2004 • 95 citations

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

2004 • 41 citations

Oncoprotein stability after tumour resection

1990 • 21 citations

Progress in Oncology

2002 • 18 citations